Results 201 to 210 of about 15,452 (227)

Dll1 and Dll4: similar, but not the same

Blood, 2009
The VEGF-Dll4-Notch1 signaling cascade has taken center stage in angiogenesis, but it now appears that Dll1 ligands have precedence in arteries and even seem to control VEGF signaling.
openaire   +2 more sources

The Clinicopathological Significance of Jagged1 and DLL4 in Gallbladder Cancer

Tumori Journal, 2016
Purpose Gallbladder cancers (GBCs) are highly aggressive gastrointestinal cancers with high mortality. Biological markers for the diagnosis, prognosis, and targeted therapy of GBCs have not been established. Methods The protein expression of Jagged1 and DLL4 in 80 adenocarcinomas (AC) and 46 squamous cell/adenosquamous carcinomas (SC/ASCs) was measured
Yuan, Luo, Zhu-Lin, Yang, Chunwei, Wang, Xiongying, Miao, Zhiyu, Liu, Daiqiang, Li, Qiong, Zou, Jinghe, Li, Lufeng, Liang, Guixiang, Zeng, Senlin, Chen   +10 more
openaire   +2 more sources

The Notch1-Dll4 signaling pathway regulates mouse postnatal lymphatic development

Blood, 2011
AbstractThe Notch signaling pathway plays a fundamental role during blood vessel development. Notch signaling regulates blood vessel morphogenesis by promoting arterial endothelial differentiation and pro-viding spatial and temporal control over “tip cell” phenotype during angiogenic sprouting.
Kyle, Niessen, Gu, Zhang, John Brady, Ridgway, Hao, Chen, Ganesh, Kolumam, Christian W, Siebel, Minhong, Yan   +6 more
openaire   +2 more sources

Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

Nature, 2006
Haploinsufficiency of Dll4, a vascular-specific Notch ligand, has shown that it is essential for embryonic vascular development and arteriogenesis. Mechanistically, it is unclear how the Dll4-mediated Notch pathway contributes to complex vascular processes that demand meticulous coordination of multiple signalling pathways.
John, Ridgway, Gu, Zhang, Yan, Wu, Scott, Stawicki, Wei-Ching, Liang, Yvan, Chanthery, Joe, Kowalski, Ryan J, Watts, Christopher, Callahan, Ian, Kasman, Mallika, Singh, May, Chien, Christine, Tan, Jo-Anne S, Hongo, Fred, de Sauvage, Greg, Plowman, Minhong, Yan   +16 more
openaire   +2 more sources

DLL4 signalling maintains organization and function of lacteals

Nature Reviews Gastroenterology and Hepatology, 2015
exaly   +2 more sources

Expression of Dll4 during mouse embryogenesis suggests multiple developmental roles

Gene Expression Patterns, 2005
Delta-Notch signalling regulates cell-fate decisions in a variety of tissues in diverse organisms, through cell-to-cell interactions. Here, we report the expression pattern of a Delta gene family member, Delta-like 4 (Dll4). Dll4 expression was analyzed in mouse embryos and selected adult organs by monitoring beta-galactosidase (beta-gal) expression ...
Rui, Benedito, António, Duarte
openaire   +2 more sources

DLL4/VEGF bispecific molecularly imprinted nanomissile for robust tumor therapy

Biomaterials
Tumor-induced angiogenesis plays a pivotal role in the progression and expansion of solid tumors, making anti-angiogenic therapies a promising strategy in cancer treatment. However, compensatory angiogenesis, which can drive drug resistance and tumor recurrence, poses significant challenges in anti-angiogenic therapy.
Fang Jin, Peixin Guan, Lingrui Huang, Anqi Zhang, Song Gao, Lisheng Wang, Zhen Liu   +6 more
openaire   +2 more sources

Dual inhibition of VEGF and DLL4 ameliorates anti-DLL4 cardiac endothelial hypertrophy in cynomolgus monkeys

Journal of Pharmacological and Toxicological Methods, 2016
Rene Meisner, Gretchen Argast, Yu-Wang Liu, Breanna Wallace, Min Wang, Ann Kapoun, Tim Hoey   +6 more
openaire   +1 more source

Epsin1-mediated exosomal sorting of Dll4 modulates the tubular-macrophage crosstalk in diabetic nephropathy

Molecular Therapy, 2023
Li Xiao
exaly  

VEGF/DLL4 BINDING AGENTS AND USES THEREOF

2019
The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind ...
openaire   +1 more source